Eckert & Ziegler

(IN BRIEF) Eckert & Ziegler has secured MDR certification for its Ru-106 eye applicators, ensuring continued availability of a critical treatment for eye cancer patients in the EU. The devices, used in brachytherapy procedures for conditions such as uveal melanoma … Read the full press release →

(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, … Read the full press release →

(IN BRIEF) Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences have scaled up production of the critical medical isotope Actinium-225, moving from development into larger-scale manufacturing at facilities in Řež and Braunschweig. The expansion … Read the full press release →

(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release →

(IN BRIEF) Eckert & Ziegler SE has been awarded the “Best Managed Companies Award” for the second time, a prestigious recognition celebrating excellence in strategy, innovation, culture, and governance. This accolade underscores the company’s continued leadership in supplying isotopes for … Read the full press release →

(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release →

(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release →

(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release →

(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release →

(IN BRIEF) Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization for Telix’s ProstACT GLOBAL Phase III study. The agreement includes supplying patients from Eckert & Ziegler’s Berlin facility and … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release →